Abstract:The fungal pathogen Cryptococcus neoformans causes up to 278 000 infections each year globally, resulting in up to 180,000 deaths annually, mostly impacting immunocompromised people. Therapeutic options for C. neoformans infections are very limited. Caspofungin, a member of the echinocandin class of antifungals, is generally well tolerated but clinically ineffective against C. neoformans. We sought to identify biological processes that can be targeted to render the cell more susceptible to echinocandins by screening the available libraries of gene deletion mutants made in the KN99α background for caspofungin sensitivity. We adapted a Candida albicans fungal biofilm assay for the growth characteristics of C. neoformans and systematically screened 4,030 individual gene deletion mutants in triplicate plate assays. We identified 25 strains that showed caspofungin sensitivity. We followed up with a dose dependence assay, and 17 of the 25 were confirmed sensitive, 5 of which were also sensitive in an agar plate assay. We made new deletion mutant strains for four of these genes: CFT1, encoding an iron transporter; ERG4, encoding a sterol desaturase; MYO1, encoding a myosin heavy chain; and YSP2, encoding a sterol transporter. All were more sensitive to membrane stress and showed significantly increased sensitivity to caspofungin at higher temperatures. Surprisingly, none showed any obvious cell wall defects such as would be expected for caspofungin-sensitive strains. Our microscopy analyses suggested that loss of membrane integrity contributed to the caspofungin sensitivity, either by allowing more caspofungin to enter or remain in the cell or by altering the location or orientation of the enzyme target to render it more susceptible to inhibition. IMPORTANCE The intrinsic resistance of Cryptococcus neoformans to the cell wall inhibitor caspofungin limits the available therapies for treating cryptococcal infections. We screened a collection of more than 4,000 gene deletion strains for altered caspofungin sensitivity to identify biological processes that could be targeted to render the cell more susceptible to caspofungin. We identified multiple genes with an effect on caspofungin susceptibility and found that they were associated with altered membrane permeability rather than the expected cell wall defects. This suggests that targeting these genes or other genes affecting membrane permeability is a viable path for developing novel therapies for treating this global fungal pathogen.

Verapamil Enhances the Activity of Caspofungin against Cryptococcus neoformans Coincides with Inhibited Ca2+ /CN Pathway and Damage with Cell Wall Integrity

In Vitro Interactions of Micafungin with Amphotericin B, Itraconazole or Fluconazole Against the Pathogenic Phase of Penicillium Marneffei.

In Vitro Activity of Verapamil Alone and in Combination with Fluconazole or Tunicamycin Against Candida Albicans Biofilms.

In Vitro and in Vivo Efficacy of a Synergistic Combination of Itraconazole and Verapamil Against Aspergillus Fumigatus

Synergistic Effect of Fluconazole and Calcium Channel Blockers against Resistant Candida albicans

Synergism of Caspofungin and Terbinafine Against Clinical and Environmental Isolates of Cryptococcus Neoformans

Inhibitory effect of verapamil on Candida albicans hyphal development, adhesion and gastrointestinal colonization.

Antifungal Effect of Vitamin D3 against Cryptococcus neoformans Coincides with Reduced Biofilm Formation, Compromised Cell Wall Integrity, and Increased Generation of Reactive Oxygen Species

In Vitro Synergistic Antifungal Activities of Caspofungin in Combination with Fluconazole or Voriconazole Against Candida Species Determined by the Etest Method

Mangiferin Enhances the Antifungal Activities of Caspofungin by Destroying Polyamine Accumulation

Membrane Integrity Contributes to Resistance of Cryptococcus neoformans to the Cell Wall Inhibitor Caspofungin

The Calcium Channel Blocker Verapamil Inhibits Oxidative Stress Response in Candida albicans

In vitro synergistic effect of minocycline combined with antifungals against Cryptococcus neoformans

Synergistic Effect of Doxycycline and Fluconazole Against Candida Albicans Biofilms and the Impact of Calcium Channel Blockers.

Synergic effect of deferoxamine combined with fluconazole against fluconazole-resistant <i>Candida</i> Spp. through inhibited Cek1 MAPK signaling pathway

Synergistic effect of eravacycline combined with fluconazole against resistant Candida albicans in vitro and in vivo

Synergistic Effect of the Combination of Deferoxamine and Fluconazole in Vitro and in Vivo Against Fluconazole-Resistant Candida Spp.

Rapamycin and caspofungin show synergistic antifungal effects in caspofungin-susceptible and caspofungin-resistant Candida strains in vitro

Antifungal activity of combination of caspofungin and voriconazole, itraconazole or amphotericin B against clinical strains of Scedosporium apiospermum in vitro

Antifungal activity and mechanism of berberine against Cryptococcus neoformans

Antifungal Activity of Antifungal Drugs, as Well as Drug Combinations Against Exophiala dermatitidis